

# Diabetes & Obesity

## RESEARCH REVIEW™

Making Education Easy

Issue 151 – 2021

### In this issue:

- Decreasing higher energy foods/portion sizes at worksite cafeterias
- Quantity/variety of food groups consumption and diabetes risk
- Efficacy of CGM on maternal and neonatal outcomes in GDM
- Effects of financial incentives and environmental strategies on weight loss
- Alcohol consumption and long-term type 2 diabetes risk after GDM
- SGLT-2 inhibitors vs. GLP agonists: CV outcome risk
- CSII vs. MDIs in emerging adults with type 1 diabetes
- Intranasal oxytocin: effects on food intake/craving
- Associations of BMI with cardiometabolic diseases
- Different effects of lifestyle intervention in high- and low-risk prediabetes
- Discontinuing CGM in type 2 diabetes treated with basal insulin
- Effects of empagliflozin on insulin therapy in type 2 diabetes with CV disease
- SGLT-2 vs. DPP-4 inhibitors in type 2 diabetes according to prior CV/kidney disease
- Glycaemic control in type 2 diabetes with high HbA<sub>1c</sub> at start of second-line therapy

## Welcome to issue 151 of Diabetes and Obesity Research Review.

This extended issue begins with a stepped-wedge RCT proving that interventions can be effective in reducing the amount of higher energy foods purchased at worksite cafeterias. On similar lines, interventions of lottery-based financial incentives and environmental change strategies were less successful for achieving meaningful weight loss among employees from three large US companies. Other included research has compared SGLT-2 inhibitors with GLP-1 receptor agonists for differential CV benefits among patients with type 2 diabetes according to the presence or absence of pre-existing CV disease. SGLT-2 inhibitors have also been compared with DPP-4 inhibitors for their capacity to reduce all-cause and CV-related mortality and hospitalisations for heart failure and CKD in patients with type 2 diabetes with or without established CV and/or renal disease.

We hope you enjoy the research selected. We appreciate feedback and suggestions from our readers, so please keep sending them.

Best regards,

Professor Jeremy Krebs

[jeremykreb@researchreview.co.nz](mailto:jeremykreb@researchreview.co.nz)

### Impact of decreasing the proportion of higher energy foods and reducing portion sizes on food purchased in worksite cafeterias

Authors: Reynolds JP et al.

**Summary:** Nineteen worksite cafeterias in the UK serving 20,327 employees introduced the replacement of higher energy products with lower energy products ('availability') and also introduced reductions in portion sizes of higher energy products ('size') in this stepped-wedge randomised trial, with the availability intervention implemented first and maintained and the size intervention added to the availability intervention; intervention categories included main meals, sides, cold drinks, snacks and desserts. There were overall reductions from baseline in energy purchased from intervention categories during both the availability and size interventions of 4.8% and 11.5% ( $p < 0.001$  for both), with the difference between the two interventions reaching statistical significance ( $p < 0.001$ ).

**Comment:** It is widely recognised that to turn around the obesity epidemic, multiple strategies are required that include both individual and population level interventions. Ultimately to achieve weight loss, individuals need to reduce their total energy intake. Anything that helps facilitate this should be embraced. Manipulating the energy density of food and portion sizes are two obvious ways to achieve this and form the basis of many weight management programmes. What this study investigated is the effect of doing this at a population/food environmental level by restricting the availability of food items in a work cafeteria. The study shows that it is possible to reduce the total energy purchased. It wasn't able to confirm that this necessarily reduced the energy consumed or weight of individuals. There are many obvious ways that might have prevented that. However, it is a promising outcome that warrants further investigation.

Reference: *PLoS Med* 2021;18:e1003743

Abstract

#### Abbreviations used in this issue

CGM = continuous glucose monitoring  
CKD = chronic kidney disease  
CSII = continuous subcutaneous insulin infusion  
CV = cardiovascular

DPP = dipeptidyl peptidase  
GDM = gestational diabetes mellitus  
GLP = glucagon-like peptide  
HbA<sub>1c</sub> = glycosylated haemoglobin

HR = hazard ratio  
MDI = multiple daily injections  
RCT = randomised controlled trial  
SGLT = sodium glucose cotransporter

## NEW ZEALAND HAS A GROWING DIABETES PROBLEM<sup>1</sup>

**WEIGHT LOSS HAS THE POTENTIAL TO INDUCE REMISSION OF TYPE 2 DIABETES IN PEOPLE WHO ARE OVERWEIGHT OR OBESE.<sup>2</sup>**  
**HELP YOUR PATIENTS MANAGE THEIR WEIGHT AND IMPROVE THEIR HEALTH.**

**References:** 1. A rising tide of type 2 diabetes in younger people: what can primary care do? BPAC. [Online]. Accessed: <https://bpac.org.nz/2018/docs/diabetes.pdf>. 2. Leon M. Primary care-led weight management for remission of type 2 diabetes (DIRECT): an open-label, cluster-randomised trial 2017; [http://dx.doi.org/10.1016/S0140-6736\(17\)33102-1](http://dx.doi.org/10.1016/S0140-6736(17)33102-1). **DUROMINE™** IS A CS CONTROLLED DRUG. **DUROMINE™** IS AN UNFUNDED MEDICINE - A PRESCRIPTION CHARGE WILL APPLY. PLEASE REVIEW FULL DATA SHEET BEFORE PRESCRIBING AVAILABLE AT [WWW.MEDSAFE.GOV.NZ](http://WWW.MEDSAFE.GOV.NZ) OR PHONE Freephone 0508 375394. Minimum Data Sheet Information (phenentermine). **DUROMINE™ Indications:** For the management of obesity as a short-term adjunct in a medically monitored weight loss programme based on exercise, diet and behaviour modification in obese patients with a body mass index (BMI) of 30 kg/m<sup>2</sup> or greater. **DUROMINE™** may appropriately be initiated in overweight patients with a lower BMI when risk of morbidity from other medical conditions is increased. **Dosage and Administration:** The usual starting dose in adults and children over 12 years is 30 mg once daily at breakfast. Continuous or inter-mittent maintenance dose is 15 mg to 30 mg once daily depending on responsiveness. Patients require medical review after a defined course of treatment, which should not exceed three months. Available in 15 mg and 30 mg capsules. **Contraindications:** Pulmonary artery hypertension, heart valve abnormalities, heart murmurs, moderate to severe hypertension, cerebrovascular disease, severe cardiac disease including arrhythmias, advanced arteriosclerosis, hypersensitivity to sympathomimetic drugs, hyperthyroidism, psychiatric illnesses, glaucoma, drug/alcohol abuse or dependence, concomitant MAOIs or within 14 days of MAOI use. **Precautions:** Short term monotherapy only. Co-administration of drug products for weight loss is not recommended. There have been no reported cases of valvular heart disease occurring with phenentermine alone. Use with caution in mild hypertension, established coronary artery disease, epilepsy, and in those receiving insulin, oral hypoglycaemic agents or psychotropic agents. **Adverse Effects:** The most common are palpitations, tachycardia, elevation of blood pressure and precordial pain. Others included restlessness, insomnia, nausea, and dry mouth. Psychotic episodes, hallucinations and serious cardiovascular or cerebrovascular events are rare. Full Data Sheet and Consumer Medicine Information is available from Medsafe at [www.medsafe.govt.nz](http://www.medsafe.govt.nz). (Inova Pharmaceuticals (Australia) Pty Limited, Level 10, 12 Help Street, Chatswood NSW 2067, Australia. Distributed in New Zealand by Radiant Health Ltd, c/o Supply Chain Solutions, 74 Westney Road, Airport Oaks, Auckland. For all product enquiries: New Zealand Toll Free: 0508 375 394. TAPS NA 12719. NZ-2021-02-0010. February 2021.



For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

[www.researchreview.co.nz](http://www.researchreview.co.nz)

a RESEARCH REVIEW™ publication




**Jardiance®**  
(empagliflozin)

**FULLY FUNDED**  
with Special Authority criteria\*  
February 1st, 2021

**NEW. For your patients with type 2 diabetes<sup>†</sup>**

THE POWER TO ACCOMPLISH MORE  
Above and beyond glycaemic control<sup>†,2</sup>

Click below to download your JARDIANCE resources

**PRESCRIBING GUIDE** **PATIENT BOOKLET**

## Quantity and variety of food groups consumption and the risk of diabetes in adults

**Authors:** Liu M et al.

**Summary:** Relationships between variety and quantity of 12 major food groups with new-onset diabetes were explored in a prospective cohort of 16,117 individuals free of diabetes at baseline in this research from China. Over a median 9.0 years of follow-up, 1088 of the participants were diagnosed with new-onset diabetes. A significant inverse association was reported between a dietary variety score and new-onset diabetes risk (HR for each 1-point incremental increase, 0.85 [95% CI 0.80, 0.90]), with significant U-shaped associations for refined grains, whole grains, nuts, red meat, poultry, processed meat, dairy products and aquatic products, and significant L-shaped associations for legumes, vegetables, fruits and eggs.

**Comment:** There is a vast array of literature on associations between various dietary components and the risk of diabetes. Studies have looked at the relative effects of macronutrients and then broken these down further; for example, saturated fat versus mono- or polyunsaturated fats. Others have examined the glycaemic response to individual foods; e.g. low versus high glycaemic index. This study takes a different approach to look at variety of foods and shows that a greater variety is associated with reduced risk of diabetes. This is another twist on the concept of dietary patterns rather than individual nutrients. It raises many questions, such as combinations or relative importance of particular food items, and as alluded to in this paper, whether there are thresholds where benefits shift to risks. These are difficult issues to resolve in experimental studies.

**Reference:** *Clin Nutr* 2021;40:5710–7  
**Abstract**

## Efficacy of continuous glucose monitoring on maternal and neonatal outcomes in gestational diabetes mellitus

**Authors:** García-Moreno RM et al.

**Summary:** This was a systematic review with meta-analysis of six RCTs comparing CGM with blood glucose level monitoring in a total of 482 women with GDM. Compared with blood glucose level monitoring, CGM use was associated with lower HbA<sub>1c</sub> levels at the end of pregnancy (mean difference, -0.22% [95% CI -0.42, -0.03]), less gestational weight gain (-1.17kg [-2.15, -0.19]) and a lower birthweight in the offspring (-116.26g [-224.70, -7.81]); there was no significant difference for any other outcome assessed.

**Comment:** The management of GDM requires intensive dietary and then often insulin therapy to achieve tight glycaemic control. Women are generally very motivated to achieve good results to achieve the best outcomes for their babies, and therefore the optimal use of newer technologies is of great interest. This paper reviewed the evidence for CGM as a tool to assist women with GDM. In a systematic review, there were very few RCTs of CGM, so the evidence base is relatively small. Despite that, the conclusion was that CGM does help women achieve better glycaemic control and also importantly less weight gain and lower birthweights, which are all associated with better pregnancy outcomes and also later metabolic outcomes for the children.

**Reference:** *Diabet Med*; Published online Sept 24, 2021  
**Abstract**

<sup>†</sup>38% RRR in CV death in patients with established CV disease (CAD, PAD, MI or stroke) and T2D (HR=0.62; p<0.001).<sup>‡</sup>  
\*JARDIANCE is a funded medicine. Restrictions apply: Pharmaceutical Schedule, Hospital Medicines List. <sup>†</sup>In adult patients with insufficiently controlled type 2 diabetes and CAD, PAD, or a history of MI or stroke. <sup>‡</sup>The absolute risk for CV death was reduced from 5.9% in patients receiving standard of care plus placebo to 3.7% in patients receiving standard of care plus JARDIANCE® (p<0.001).<sup>1,2</sup>

1. JARDIANCE® Data Sheet 2019 2. Zinman B et al. *N Engl J Med*. 2015;373(22):2117-2128

**JARDIANCE® empagliflozin 10mg, 25mg film coated tablets** Before prescribing, please review full Data Sheet which is available on request from Boehringer Ingelheim or from <http://www.medsafe.govt.nz/profs/datasheet/dsform.asp>  
**INDICATION:** *Glycaemic control:* Treatment of type 2 diabetes mellitus (T2DM) to improve glycaemic control in adults as: *Monotherapy:* When diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance; *Add-on combination therapy:* With other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control. *Prevention of cardiovascular (CV) death:* In patients with T2DM and established CV disease to reduce the risk of CV death. To prevent CV deaths, JARDIANCE® should be used in conjunction with other measures to reduce CV risk in line with the current standard of care. **DOSAGE AND ADMINISTRATION:** Recommended starting dose is 10mg once daily taken with or without food. Dose can be increased to 25mg once daily. No dose adjustment is necessary for patients based on age, patients with eGFR ≥30mL/min/1.73m<sup>2</sup> or hepatic impairment. When JARDIANCE® is used in combination with a sulfonylurea (SU) or with insulin, a lower dose of the sulfonylurea or insulin may be considered. **CONTRAINDICATIONS:** Hypersensitivity to empagliflozin or any of the excipients; patients with CKD stage 4 or 5 (severely impaired renal function including patients receiving dialysis; eGFR <30mL/min/1.73m<sup>2</sup> or CrCl <30mL/min). **WARNINGS AND PRECAUTIONS:** Patients with type 1 diabetes; diabetic ketoacidosis; necrotising fasciitis of the perineum (Fournier's gangrene); discontinue when eGFR is below 30mL/min/1.73m<sup>2</sup>; assess renal function before treatment and regularly thereafter; patients for whom a drop in BP could pose a risk (e.g. those with known CV disease, on anti-hypertensive therapy with a history of hypotension, or aged ≥75 years); urinary tract infections (UTIs); rare hereditary conditions of galactose intolerance, e.g. galactosaemia; pregnancy; lactation; children (<18 years). **INTERACTIONS:** Diuretics; insulin and SU; interference with 1,5-anhydroglucitol assay. **ADVERSE REACTIONS:** *Very common:* hypoglycaemia (when used with combination with SU or insulin). *Common:* hypoglycaemia (combination with metformin; pioglitazone with or without metformin; metformin and linagliptin); vaginal moniliasis, vulvovaginitis, balanitis and other genital infections; UTIs (including pyelonephritis and urosepsis); pruritus; allergic skin reactions (e.g. rash, urticaria); increased urination; thirst; serum lipids increased; volume depletion (patients aged ≥75 years). For other adverse reactions, see full Data Sheet. **ACTIONS:** Empagliflozin is a reversible, highly potent and selective competitive inhibitor of sodium-glucose co-transporter 2 (SGLT2), which is responsible for glucose absorption in the kidney. It improves glycaemic control in patients with type 2 diabetes by reducing renal glucose reabsorption through SGLT2. Through inhibition of SGLT2, excessive glucose is excreted in urine. **PRESCRIPTION MEDICINE.** JARDIANCE® is a funded medicine - Restrictions apply: Pharmaceutical Schedule, Hospital Medicines List. BOEHRINGER INGELHEIM (NZ) Ltd. Level 3, 2 Osterley Way, Manukau Auckland 2104. TAPS MR7142/PC-NZ-100168 BOE000370



Boehringer Ingelheim (NZ) Ltd.  
PO Box 76216 Manukau City,  
Auckland 2241. Phone 0800 802 461



Eli Lilly and Company (NZ) Ltd.  
PO Box 109197 Newmarket,  
Auckland 1149. Phone 0800 500 056  
NZBN 9429039560643

For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)





**trulicity**  
dulaglutide once-weekly injection



**New Zealand's only funded  
GLP-1 RA is now available for  
adults with type 2 diabetes.\*1-3**

\*Special Authority Criteria Apply.<sup>2</sup>

**PLEASE REVIEW FULL DATA SHEET BEFORE PRESCRIBING.  
FULL DATA SHEET CAN BE ACCESSED AT [WWW.MEDSAFE.GOV.NZ](http://WWW.MEDSAFE.GOV.NZ)  
OR ON REQUEST BY CALLING 0800 500 056.**

**TRULICITY®** (dulaglutide 1.5mg/0.5mL solution for injection, pre-filled pen [autoinjector]). **PRESCRIPTION MEDICINE. TRULICITY is funded under the New Zealand Pharmaceutical Schedule from 1 September 2021. Special Authority Criteria apply. INDICATIONS** – TRULICITY is indicated for adult patients with Type 2 diabetes as 1) an adjunct to diet and exercise to improve glycaemic control; and 2) as an adjunct to standard of care therapy to reduce the risk of major adverse cardiovascular events in those with either established cardiovascular disease or multiple risk factors for cardiovascular disease. **CONTRAINDICATIONS** – Hypersensitivity to dulaglutide or any of the excipients. **PRECAUTIONS** – should not be used in patients with Type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis; severe gastrointestinal disease – not recommended; acute pancreatitis – discontinue treatment if suspected; hypoglycaemia – combining treatment with sulfonylurea or insulin may increase risk; congestive heart failure – limited therapeutic experience; Use in Pregnancy Category B3. **ADVERSE EFFECTS Clinical Trials Experience** – Very Common (≥10%) gastrointestinal disorders (nausea, vomiting and diarrhoea), hypoglycaemia (in combination with insulin non-/secretagogues and/or insulin); Common (≥1 and <10%) abdominal pain, decreased appetite, dyspepsia, fatigue, hypoglycaemia (as monotherapy), immunogenicity, atrial fibrillation. **DOSAGE AND ADMINISTRATION** – **Dosage:** Adults (≥18 years): 1.5 mg once weekly, at any time of day, independently of meals. Elderly Patients (≥65 years): dose adjustment not required. Children and adolescents (<18 years): safety and effectiveness have not been established. Renal Impairment: no dose adjustment is required in mild, moderate or severe renal impairment; not recommended in end-stage renal disease. Hepatic Impairment: no dose adjustment required. **Administration:** subcutaneous injection in the abdomen, thigh or upper arm. Should not be administered intravenously or intramuscularly. Single-use in one patient only. Discard the pen once the injection is completed. Please review full Data Sheet before prescribing. Full Data Sheet is available on request from Eli Lilly, Eli Lilly and Company (NZ) Limited, PO Box 109 197, Newmarket, Auckland 1149. Phone 0800 500 056. Based on Data Sheet approved 12 August 2021.

**Abbreviation:** GLP-1 RA, Glucagon-like peptide-1 receptor agonist.

**References:** 1. Trulicity Data Sheet August 2021. 2. Pharmaceutical Schedule. Available at: <https://schedule.pharmac.govt.nz/ScheduleOnline.php>. Last Accessed September 2021. 3. Trulicity Product Detail. Medsafe. Available at: <https://www.medsafe.govt.nz/regulatory/ProductDetail.asp?ID=21737>. Last accessed September 2021.

Trulicity® is a registered trademark of Eli Lilly and Company (NZ) Limited, PO Box 109 197 Newmarket, Auckland 1149, New Zealand. NZBN 9429039560643. Telephone 0800 500 056.

PP-DG-NZ-0039. TAPS BG1593. ELI4479  
Date of preparation: September 2021.

*Lilly*

## Effect of financial incentives and environmental strategies on weight loss in the healthy weigh study

**Authors:** Glanz K et al.

**Summary:** Employees with a BMI of 30–55 kg/m<sup>2</sup> and ≥1 other CV risk factor were enrolled in a 2×2 factorial randomised trial comparing the effects of 18 months of lottery-based financial incentives, environmental strategies and their combination with usual care on weight loss and maintenance; 86 participants were randomised to each of the four groups. Relative to usual care, participants assigned to the incentives, environmental strategies and combined incentives plus environmental strategies groups had mean weight losses at 18 months (primary endpoint) of 2.45kg, 1.00kg and 1.09kg, but none of these differences achieved statistical significance; similar nonsignificant differences persisted 6 months later (i.e. 6 months after the interventions had finished).

**Comment:** The main message I take from this paper is that helping people to lose weight is really hard! Most people who are obese would like to lose weight and most have tried. Sadly, few are successful, particularly in the long-term. Many barriers and facilitators have been described, and these include support from an external agent and financial incentives. These were studied in this trial, either alone or in combination. Neither were particularly effective in the way they were used here. This may be because they aren't effective or because the delivery was not intensive enough. That all feels a bit depressing doesn't it, but we mustn't give up. The DiRECT study amongst others have given us clear evidence that when people do achieve meaningful weight loss, it really makes a difference to their health.

**Reference:** *JAMA Netw Open* 2021;4:e2124132

[Abstract](#)

## Association of habitual alcohol consumption with long-term risk of type 2 diabetes among women with a history of gestational diabetes

**Authors:** Hinkle SN et al.

**Summary:** The association of alcohol consumption with type 2 diabetes risk was explored in a US Nurses' Health Study II cohort of 4740 women with a history of GDM. Over a median 24 years of follow-up (78,328 person-years), the incidence of type 2 diabetes was 19%. Compared with no alcohol consumption, consumption of 5.0–14.9 g/day was associated with a lower risk of incident type 2 diabetes (adjusted HR 0.45 [95% CI 0.33, 0.61]), with no associations detected for other alcohol consumption ranges assessed (0.1–4.9 and ≥15.0 g/day); similar results were obtained after additional adjustment for BMI (HR for 5.0–14.9 g/day, 0.59 [0.42, 0.81]) with the other two alcohol consumption ranges still not significantly associated.

**Comment:** Women with a history of GDM are at greater risk of developing type 2 diabetes later in life than women who do not develop GDM. The actual increase in risk varies across studies, and is of course influenced by other individual risk factors, such as weight, family history and exercise. It is worth noting that in this study of nurses in the US, the rate of developing diabetes was 19% over a median of 24 years. This paper reported on the association between level of habitual alcohol use and risk of developing type 2 diabetes in women with a history of GDM. It may come as a relief to many that, as has been reported in other situations, a low level consumption of alcohol was associated with a reduced risk of type 2 diabetes. That glass of chardonnay as you are preparing the kids' meals may be just the answer. Of course there are many other considerations, and the slippery slope of the second and third glasses that can so easily happen!

**Reference:** *JAMA Netw Open* 2021;4:e2124669

[Abstract](#)

**Independent Content:** The selection of articles and writing of summaries and commentary in this publication is completely independent of the advertisers/sponsors and their products.

**Privacy Policy:** Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time.

**Disclaimer:** This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.

**Research Review publications are intended for New Zealand health professionals.**



**Saxenda®**  
liraglutide (rys)

*I have the will to train  
three times a week.  
But I still need help to lose  
weight and keep it off.*

**MICHAEL; Age: 38 BMI: 34**  
Patient portrayal



Visit **SAXENDACARE.CO.NZ** to learn more.  
Click below to download your Saxenda® resources.

**PRESCRIBING GUIDE**

**PATIENT BOOKLET**

Saxenda® is an unfunded prescription medicine. Doctor's fees and pharmacy charges may apply. Please review Data Sheet before prescribing. The Data Sheet can be accessed at [www.novonordisk.co.nz](http://www.novonordisk.co.nz)

**SAXENDA® (liraglutide (rys) 6 mg/mL). Indication:** As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index of  $\geq 30$  kg/m<sup>2</sup> (obese) or  $\geq 27$  kg/m<sup>2</sup> to  $<30$  kg/m<sup>2</sup> (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea. Treatment should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight. **Dose/administration:** Administered subcutaneously once daily at any time, independent of meals; starting dose 0.6 mg/day; increase to 3.0 mg/day in increments of 0.6 mg per week. If escalation to the next dose is not tolerated for two consecutive weeks, consider discontinuing treatment. Daily doses higher than 3.0 mg are not recommended. Must not be administered intravenously or intramuscularly. **Contraindications:** Hypersensitivity to liraglutide or any of its excipients. **Warnings/Precautions:** Not for use in patients: with obesity secondary to endocrinological or eating disorders or to treatment with medicinal products that may cause weight gain; children ( $<18$  years); with a history of pancreatitis, severe renal impairment including end-stage renal disease, hepatic impairment or insufficiency, inflammatory bowel disease or diabetic gastroparesis;  $\geq 75$  years. Must not be used as a substitute for insulin. Should not be used: with insulin; in combination with other prescription, over-the-counter or complementary medicines intended for weight loss. Use with caution in patients: 65-74 years; with thyroid disease; on other drugs that increase heart rate. Advise patients of the potential risk of dehydration in relation to gastrointestinal side effects and to take precautions to avoid fluid depletion. If pancreatitis is suspected, treatment should be discontinued and appropriate management initiated. If acute pancreatitis is confirmed, Saxenda® should not be restarted. A higher rate of cholelithiasis and cholecystitis has been observed in patients treated with Saxenda® - patients should be informed of the characteristic symptoms. Cholelithiasis and cholecystitis may lead to hospitalisation and cholecystectomy. Saxenda® should be discontinued for patients who experience a sustained increase in resting heart rate. Reducing the dose of concomitantly administered insulin secretagogues to reduce the risk of hypoglycaemia should be considered. Pregnancy Category B3. Not for use during pregnancy or breastfeeding. **Undesirable effects:** Very Common: nausea, vomiting, diarrhoea, constipation, headache. Common: dyspepsia, abdominal pain upper, abdominal distension, eructation, flatulence, gastroesophageal reflux disease, dry mouth, gastritis, hypoglycaemia, injection site reactions, fatigue, asthenia, dizziness, dysgeusia, cholelithiasis, insomnia, increased lipase, increased amylase. (April 2021)

Novo Nordisk Pharmaceuticals Ltd., Auckland, New Zealand. NovoCare®  
Customer Care Center (NZ) 0800 733 737. [www.novonordisk.co.nz](http://www.novonordisk.co.nz).  
® Registered trademark of Novo Nordisk A/S. ANZZ15X00022. TAPS BG1054.  
Prepared: August 2021.



For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

## Sodium-glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease

**Authors:** Patomo E et al.

**Summary:** These researchers investigated the differential CV benefits of SGLT-2 inhibitors versus GLP-1 receptor agonists in population-based propensity score-matched cohorts of patients with type 2 diabetes with (52,901 pairs) and without (133,139 pairs) CV disease. Compared with starting a GLP-1 receptor agonist, starting an SGLT-2 inhibitor was associated with a lower risk of myocardial infarction or stroke in the presence of CV disease (HR 0.90 [95% CI 0.82, 0.98]) but not in its absence (1.07 [0.97, 1.18]), and also a lower risk of hospitalisation for heart failure, this time in patients with and those without CV disease (0.71 [0.64, 0.79] and 0.69 [0.56, 0.85], respectively).

**Comment:** Now that we have access to a funded SGLT-2 inhibitor and a GLP-1 agonist for many people with type 2 diabetes, the obvious question is when is one agent better than the other? Unfortunately, we do not have any large RCTs with hard outcome measures comparing the two classes to inform this question. From the existing placebo controlled trials within each class, there are some apparent differences. For example, SGLT-2 inhibitors have strong evidence to support a reduction in heart failure admissions, which GLP-1 agonists do not. GLP-1 agonist appear to reduce the risk of stroke, which is not necessarily supported for SGLT-2 inhibitors. This paper reports matched individuals starting either class of drug, and outcomes according to previous CV disease. The key thing here is that they were not randomly allocated to the drug, but they are real-world patients. The data support the difference in risk of heart failure and possibly a small benefit to SGLT-2 inhibitors in CV disease for those with existing CV disease. In the absence of heart failure, I think we can say for now that the decision between agents may best be informed by patient choice and side-effect profile.

**Reference:** *Ann Intern Med* 2021;174:1528-41  
[Abstract](#)

## Use of continuous subcutaneous insulin infusion versus multiple daily injections in emerging adults with type 1 diabetes is associated with better clinical engagement but not glycaemic control

**Authors:** Chai TYL et al.

**Summary:** These researchers assessed glycaemic control and utilisation of services for a retrospective cohort of 318 emerging adults with type 1 diabetes on MDIs or CSIs; 176 of the patients were receiving MDIs, 121 were receiving CSIs and 21 switched from MDIs to CSIs. There was no significant difference between CSI versus MDI recipients for aggregated mean HbA<sub>1c</sub> level (9.1% vs. 9.3% [ $p=0.23$ ]); however, CSI users had a significantly greater mean change in HbA<sub>1c</sub> level at 3 years of 0.55% ( $p<0.01$ ) while MDI users had no significant change. CSI recipients also exhibited improvements in clinic visits compared with MDI recipients (2.8 vs. 2.5 per year [ $p=0.02$ ]), whereas admissions for diabetic ketoacidosis were similar at 3.6 per 100 patient-years.

**Comment:** This paper caught my eye, mainly because I was curious what an emerging adult was! Images of cocoons came to mind. Anyway, this very real-world retrospective audit of a young adult diabetes clinic makes some interesting observations. There is often a belief that insulin pumps are somehow the holy grail of diabetes management, and I think both patients, parents and members of the diabetes team sometimes can forget that they are just a tool to deliver insulin. For some people who use the tool to its best advantage, there is no doubt that they can achieve much better results in managing their glucose levels than they could with multiple injections. However, this paper reminds us that that is not the case for everyone. It also reminds us that the group of 'emerging adults' pose many challenges to trying to achieve tight glycaemic control and reducing the risks of complications.

**Reference:** *Intern Med J*; Published online Sept 24, 2021  
[Abstract](#)

**RACP MyCPD Program participants** can claim **one credit per hour** (maximum of 60 credits per year in Category One – Educational Activities) for reading and evaluating Research Reviews.  
Please [CLICK HERE](#) to download CPD Information



## Intensify treatment early with GALVUS® and GALVUMET® for durable HbA1c control<sup>1</sup>

For your type 2 diabetes patient not reaching their HbA1c target, GALVUS and GALVUMET remain an effective, subsidised treatment strategy.<sup>1-3</sup>

GALVUS and GALVUMET have an established safety profile with good tolerability.<sup>2,4,5,6,7</sup>

**STILL FULLY FUNDED FOR PATIENTS WITH TYPE 2 DIABETES**  
**NO special authority required<sup>3</sup>**



*The time is now*

**References:** 1. Matthews DR, et al. Diabet Med. 2019;36:505-13 (and supplementary appendix). 2. Bosi E, et al. DiabetesCare 2007;30(4):890-895. 3. Pharmaceutical Schedule, available at [www.pharmac.govt.nz](http://www.pharmac.govt.nz). Last accessed January 2021. 4. Lukashevich V, et al. Diabetes Obes Metab 2014;16:403-409. 5. GALVUS® Data Sheet 1 July 2020. 6. GALVUMET Data Sheet 2 September 2020. 7. Ferrannini E, et al. Diabetes Obes Metab 2009;11(2):157-166.

**PRESCRIPTION MEDICINE** for the treatment of Type 2 diabetes. GALVUS® (vildagliptin) 50 mg tablets and GALVUMET® (vildagliptin/metformin hydrochloride) 50 mg/850 mg and 50 mg/1000 mg tablets.

Before prescribing please review the datasheet for information on dosage, contraindications, precautions, interactions and adverse effects available at [www.medsafe.govt.nz](http://www.medsafe.govt.nz) or [click here](#) for Product Information. GALVUS and GALVUMET are fully funded medicines and registered trademarks of Novartis AG, Switzerland.

NZ-00925 March 2021 TAPS NA12763 essence NV10186



For more information, please go to [www.medsafe.govt.nz](http://www.medsafe.govt.nz)

[www.researchreview.co.nz](http://www.researchreview.co.nz)



## Effects of intranasal oxytocin in food intake and craving

**Authors:** Chen C-Y et al.

**Summary:** This was a meta-analysis of twelve clinical trials in 266 non-psychiatric and 157 psychiatric participants reporting on the effects of intranasal oxytocin on food intake, craving, anxiety and stress reduction. Single-dose intranasal oxytocin induced significant reductions in food intake in non-psychiatric participants (standardised mean difference, -0.66 [95% CI -1.18, -0.14]), but there was no significant effect seen in those with anorexia nervosa, bulimia nervosa/binge eating disorder or schizophrenia. Additional analyses on leisure foods also showed there was a reduction in chocolate biscuit consumption in non-psychiatric participants. Intranasal oxytocin had no significant impact on food craving or hunger compared with placebo for the non-psychiatric participants or those with bulimia nervosa/binge eating disorder or schizophrenia, nor did it significantly affect anxiety or stress in any subgroup.

**Comment:** The hormonal regulation of appetite is complex, and we keep discovering new players and complex interactions. Oxytocin may be one of these. This meta-analysis looked at whether intranasal oxytocin had an effect on food behaviours. It is somewhat complicated by patient populations studied, and divides the results between those with psychiatric disease and those without. Oxytocin did reduce food intake as a single dose in those with no psychiatric disease, and could be further explored as a treatment strategy for obesity. Of course there is a major difference between single doses and ongoing regular treatment, particularly whether there is effect modification with repeated dosing. However, this does look promising.

**Reference:** *Clin Nutr* 2021;40:5407-16

[Abstract](#)

## Association of body mass index and its long-term changes with cardiometabolic diseases

**Authors:** Guo J et al.

**Summary:** Relationships of BMI and its long-term changes with cardiometabolic diseases, and the role of familial background and a healthy lifestyle on these associations, were explored in 36,622 individuals aged ≥40 years who were free of cardiometabolic disease and with 25-35 years of follow-up from baseline from the Swedish Twin Registry; 44.2% of the participants had a BMI ≥25 kg/m<sup>2</sup> (i.e. overweight/obese) and 30.6% developed cardiometabolic diseases during follow-up. Compared with BMIs 20-25 kg/m<sup>2</sup>, individuals with a BMI of ≥25 kg/m<sup>2</sup> were at significantly increased risk of developing any cardiometabolic disease (HR 1.52 [95% CI 1.45, 1.58]). Compared with individuals who had a stable BMI of 20-25 kg/m<sup>2</sup>, the risk of developing a cardiometabolic disease was increased in those who were overweight/obese in early life only, in later life only and both early and later life (respective HRs 1.28 [95% CI 1.02, 1.59], 1.33 [1.24, 1.43] and 1.69 [1.55, 1.85]). Stratified Cox analyses for cardiometabolic disease-discordant twin pairs revealed a significant association between overweight/obesity and increased cardiometabolic disease risk (HR 1.37 [95% CI 1.18, 1.61]), and a joint effect analysis revealed that the increased cardiometabolic diseases risk related to overweight/obesity was attenuated by 32% for those who adopted favourable lifestyle choices (1.51 [1.44, 1.58]) compared with those who did not (2.20 [2.03, 2.38]).

**Comment:** Nature or nurture – the age old debate. If there was any health parameter to which this debate is relevant, then weight and obesity is surely the best example. Twin studies have classically been the model used to try and answer the relative contributions of genetics versus environment. This paper reports on the association between obesity and cardiometabolic disease using data from the Swedish Twin Registry, to try to tease out the relative effects of obesity from other genetic factors. What do you know, its complex! There is almost certainly an interaction between genetics and environment, with lifestyle factors either attenuating or exacerbating the underlying genetic risk. You can't choose your parents, but you can choose your dinner.

**Reference:** *Clin Nutr* 2021;40:5467-74

[Abstract](#)



This Research Review has been endorsed by The Royal New Zealand College of General Practitioners (RNZCGP) and has been approved for up to 1 CME credit for the General Practice Educational Programme (GPEP) and Continuing Professional Development (CPD) purposes. You can record your CME credits in your [RNZCGP Dashboard](#)



Time spent reading this publication has been approved for CNE by The College of Nurses Aotearoa (NZ) for RNs and NPs. For more information on how to claim CNE hours please [CLICK HERE](#).



## Different effects of lifestyle intervention in high- and low-risk prediabetes

**Authors:** Fritsche A et al.

**Summary:** This trial conducted in 1105 individuals with prediabetes randomised those with a high-risk phenotype to a conventional lifestyle intervention or an intensified version in which the exercise requirements were doubled; those with a low-risk phenotype were randomised to a conventional lifestyle intervention or a control group, and 82% of participants completed the study. In the high-risk group, a significant difference was seen between the intensified versus conventional lifestyle intervention for reductions in postchallenge glucose level ( $-0.29$  mmol/L [ $p=0.025$ ]), liver fat ( $-1.34$  percentage points [ $p=0.002$ ]) and CV risk ( $p=0.007$ ). Moreover, the likelihood of glucose level tolerance normalisation was greater in the intensive intervention group over 3 years of follow up ( $p=0.008$ ).

**Comment:** If we think type 2 diabetes is very heterogeneous, then prediabetes is an even greater quagmire! We have three different ways of defining it, with fasting glucose levels, oral glucose tolerance tests and HbA<sub>1c</sub> levels, which overlap but do not identify the same people, nor the same risk of progression to diabetes. Furthermore, some people regress to 'normal' or never progress beyond very low levels of HbA<sub>1c</sub> or glucose. Therefore, developing policies for interventions is challenging to balance the investment in individual interventions versus public health approaches. This would be made easier if it were possible to identify individuals who were most at risk of progression to diabetes or adverse outcomes for whom targeted intensive interventions could be directed. This study takes a somewhat crude approach to this and shows that there is merit in following this path. What is needed is a simple tool to identify individuals with prediabetes at greatest risk that can be easily applied in primary care.

**Reference:** *Diabetes*; Published online Sept 16, 2021

[Abstract](#)

## The effect of discontinuing continuous glucose monitoring in adults with type 2 diabetes treated with basal insulin

**Authors:** Aleppo G et al., for the MOBILE Study Group

**Summary:** Adults with type 2 diabetes receiving basal without bolus insulin were initially randomised to real-time CGM or blood glucose level monitoring for 8 months, which was followed by an additional 6 months during which the blood glucose level monitoring group continued their assigned treatment ( $n=57$ ) and the CGM group was rerandomised to continue CGM ( $n=53$ ) or discontinue CGM and resume blood glucose level monitoring ( $n=53$ ). In the initial CGM group, there was an improvement in mean time in glucose level range (70–180 mg/dL) from 38% prior to CGM initiation to 62% after 8 months of CGM, and for those who then discontinued CGM, it had fallen significantly to 50% at 14 months ( $p=0.01$ ), whereas it remained stable (1% change) for those who continued CGM use; the difference between the initial CGM recipients who continued versus discontinued CGM at this time was  $-6\%$  ( $p=0.20$ ).

**Comment:** There are so many variables that determine whether a person with diabetes, type 1 or 2, achieves good glycaemic control. In people using insulin therapy, one of the most important factors is having real-time data on glucose levels. For over 30 years this has been possible with capillary glucose level monitoring, which was a major step forward from previous retrospective and very crude information from urine dipstick testing. However, finger prick testing is still invasive and there are many barriers to frequent testing. Furthermore, data are single timepoints with no trend data. For these reasons, interstitial CGM has become a very attractive option, particularly for those people who for whatever reason do very few capillary tests. In NZ where these are not funded, people decide whether they self-fund this technology or not. In clinic, I am always concerned that those who do a few tests and then trial CGMs but decide not to continue to use them will then do even fewer capillary tests. This paper to some extent confirms that concern.

**Reference:** *Diabetes Care*; Published online Sept 29, 2021

[Abstract](#)

## Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease

**Authors:** Vaduganathan M et al.

**Summary:** These researchers assessed changes in insulin use in the EMPA-REG OUTCOME trial, which randomised 7020 patients with type 2 diabetes and CV disease to receive empagliflozin 10mg, empagliflozin 25mg or placebo, and followed them for a median of 3.1 years; changes in background antihyperglycaemic therapy were permitted after 12 weeks on the study. Among 3633 trial participants not receiving insulin at baseline, empagliflozin recipients (both doses pooled) were significantly less likely to start insulin during the trial than placebo recipients (7.1% vs. 16.4%; adjusted HR 0.40 [95% CI 0.32, 0.49]). Among the 3387 participants receiving insulin at baseline, a smaller proportion of those assigned to the empagliflozin arms versus placebo arm needed to increase their insulin dose by  $>20\%$  (14.4% vs. 29.3%; adjusted HR 0.42 [95% CI 0.36, 0.49]) and a greater proportion were able to sustain a  $>20\%$  insulin dose reduction without impacting their HbA<sub>1c</sub> level (9.2% vs. 4.9%; 1.87 [1.39, 2.51]). The findings were consistent in sensitivity analyses for insulin dose changes of  $>10\%$  and  $>30\%$ .

**Comment:** By now you will be familiar with the EMPA-REG trial, which provides the main evidence for benefit of empagliflozin in reducing CV risk. This paper reports a secondary analysis from the EMPA-REG trial on the impact of empagliflozin on insulin requirements in this population. After 12 weeks of the study, investigators could add or adjust insulin therapy as required to achieve glycaemic control. In participants who were not using insulin at the start of the trial, there was a 60% reduction in the need to initiate insulin. In those already using insulin, there was a major reduction in the escalation of insulin dosing required. Both are important findings and benefit patients by reducing the burden of injections and of risks for hypoglycaemia and weight gain. These observations are over the mean 3-year follow-up, and of course can't tell us how sustained the effects are. The nature of type 2 diabetes is such that it is likely that many patients will still need to start insulin at some point, but any delay in that is useful.

**Reference:** *Diabetes Obes Metab* 2021;23:2775–84

[Abstract](#)

New Zealand Research Review subscribers can claim CPD/CME points for time spent reading our reviews from a wide range of local medical and nursing colleges. Find out more on our [CPD page](#).

### Independent commentary by Professor Jeremy Krebs MBChB, FRACP, MD

Professor Krebs is an Endocrinologist with a particular interest in obesity and diabetes. He trained in Endocrinology at Wellington Hospital in New Zealand and then did his doctorate with the Medical Research Council - Human Nutrition Research unit in Cambridge England. His thesis was on the impact of dietary factors on obesity and insulin resistance. Professor Krebs returned to New Zealand in 2002 to take up a consultant Endocrinology post at Wellington Hospital, where he was Clinical Leader of Endocrinology and Diabetes. He heads the research group and is Professor with the University of Otago, and former Director of the Clinical Research Diploma at Victoria University - which he established. As well as clinical and teaching activities, Professor Krebs maintains active research interests in the area of obesity and diabetes, with a particular focus on the association between obesity and type 2 diabetes, both from an aetiology and management perspective, with a focus on nutritional aspects, bariatric surgery and diabetes service delivery.



## Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease

Authors: Idris I et al.

**Summary:** These researchers assessed the relative impacts of SGLT-2 inhibitors and DPP-4 inhibitors on all-cause mortality, CV-related death and hospitalisation for heart failure or CKD in a retrospective UK primary-care cohort of individuals with type 2 diabetes with or without established CV and/or renal disease; 24,438 SGLT-2 inhibitor recipients were each propensity score matched to a DPP-4 inhibitor recipient. Compared with DPP-4 inhibitors, SGLT-2 inhibitors were associated with reductions in all-cause mortality, CV-related mortality, hospitalisation for heart failure and hospitalisation for CKD across the entire cohort; SGLT-2 inhibitors remained protective in patients with established or at high risk for CV disease for these four outcomes and hospitalisation for stroke (relative HRs 0.69 [95% CI 0.59, 0.82], 0.76 [0.62, 0.95], 0.73 [0.63, 0.85], 0.49 [0.43, 0.54] and 0.75 [0.59, 0.94]), and in patients with no history of CV and/or renal disease for all-cause mortality, hospitalisation for heart failure and hospitalisation for CKD (0.71 [0.57, 0.88], 0.76 [0.59, 0.98] and 0.75 [0.63, 0.88]).

**Comment:** The large RCTs of SGLT-2 inhibitors have provided robust evidence for benefit of this class to reduce the risk of CV disease and renal outcomes compared with placebo. However, as is always the case with these types of studies, the selection of participants often excludes many of the patients that we might consider using the drug in, and may not compare the drug with alternative agents that we might be considering. Therefore the type of study reported here, which even though limited by being retrospective and not randomised, do give very useful real-world data to inform practice. What this study shows is that compared with DPP-4 inhibitors, the SGLT-2 inhibitors have a very clear advantage in reducing the risk of hard endpoints, and therefore should wherever possible be added in to the regimen ahead of DPP-4 inhibitors. What is equally important from these data is that this applies to those who do not have existing CV or renal disease, which has not been clear from the large RCT data.

Reference: *Diabetes Obes Metab* 2021;23:2207–14

[Abstract](#)

## What are the factors associated with long-term glycaemic control in patients with type 2 diabetes and elevated glycated haemoglobin ( $\geq 7.0\%$ ) at initiation of second-line therapy?

Authors: Bonnet F et al.

**Summary:** This analysis of data from the global, prospective, 3-year observational DISCOVER study sought to identify factors associated with good long-term glycaemic control in 7575 participants with an HbA<sub>1c</sub> level of  $\geq 7.0\%$ , 2233 of whom had a level  $\geq 9.0\%$ , at initiation of second-line glucose-lowering therapy. The respective proportions of those with baseline HbA<sub>1c</sub> levels of 7.0– $<9.0\%$  and  $\geq 9.0\%$  who had achieved a level of  $<7.0\%$  at 6 months were 43.7% and 24.2%, and at 3 years, the corresponding proportions were 45.8% and 29.3%. For achieving an HbA<sub>1c</sub> level of  $<7.0\%$  at 3 years, the strongest predictor was having a level of  $<7.0\%$  (vs.  $\geq 7.0\%$ ) at 6 months (odds ratios 2.01 [95% CI 1.77, 2.27] and 2.68 [2.10, 3.41] for the respective baseline 7.0– $<9.0\%$  and  $\geq 9.0\%$  groups), and the likelihood was reduced by a longer duration of type 2 diabetes.

**Comment:** Clinical inertia is an important phenomenon in the management of type 2 diabetes. I have previously included studies that have looked at the patient and clinician factors which influence this. This paper reports on factors which determine the longer-term likelihood of achieving target HbA<sub>1c</sub> level once a second-line agent is actually introduced. It might seem intuitive that the strongest predictor of good long-term control was achieving this within 6 months, and that the higher the HbA<sub>1c</sub> level at the time of initiation of a second agent, the less likely that was. Both speak to the importance of early and aggressive glycaemic management.

Reference: *Diabetes Obes Metab* 2021;23:2336–43

[Abstract](#)

[CLICK HERE](#) to read previous issues of Diabetes & Obesity Research Review

## SPECIAL REPORT ON THE 2021 NZSSD Type 2 Diabetes Management Guidelines

This Special Report by Dr Ryan Paul, who was the lead on the guidelines working party, provides a summary of and commentary on the Type 2 Diabetes Management Guidance for the busy health care worker.

[CLICK HERE](#) to read the PDF online



Join us today.  
[www.nzma.org.nz](http://www.nzma.org.nz)  
or scan the code above

At all stages of your medical career, the NZMA is your voice, advocating on the issues that affect you, your colleagues and the health of all New Zealanders. A strong membership means we can do more.



[CLICK HERE](#) to read our

## Educational Series on Countering Vaccine Misinformation: A Practical Guide for Healthcare Providers

This article discusses vaccine misinformation and how it can undermine vaccine confidence and lead to vaccine hesitancy. Evidence-based strategies for countering vaccine hesitancy and misinformation are summarised. Techniques to support healthcare providers when engaging with individuals whose vaccine hesitancy has resulted from exposure to vaccine misinformation are provided.



Kindly Supported by

